StockData

Biodesix vs Castle Biosciences

BDSX and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDSX and CSTL compare

Castle Biosciences is the larger company, worth 9.9 times as much as Biodesix ($1.0B against $104M).

Biodesix grew revenue faster over the last twelve months (31.2% versus 9.8% for Castle Biosciences).

Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −25.7% at Biodesix.

Castle Biosciences scores higher on the StockData Score (11 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDSXCSTL
Size and price
Market cap$104M$1.0B
Share price$9.88$33.79
Change, 1 year24.3%−3.0%
Change, 5 years−92.3%−28.9%
Beta (5Y)0.741.38
Employees334883
StockData Score
Total score411 (better)
Valuation score02 (better)
Growth score22
Performance score13 (better)
Health score14 (better)
Dividend score00
Valuation
P/S1.0× (better)2.7×
P/B12.0×2.2× (better)
P/FCF–260×
FCF yield−18.3%0.38% (better)
Fair value–$34.71
Margin of safety–2.6%
Growth
Revenue growth (TTM)31.2% (better)9.8%
Revenue growth, 5Y average14.2%40.6% (better)
Profitability
Gross margin–77.1%
Operating margin−18.7%−7.4% (better)
Net margin−25.7%−6.1% (better)
FCF margin−18.1%1.1% (better)
Return on equity−779%−4.9% (better)
Return on invested capital−55.4%−11.1% (better)
Financial health
Debt / equity5.430.02 (better)
Interest coverage−2.5× (better)−51.2×
Current ratio2.965.28 (better)
Altman Z-score−6.246.63 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield−31.4%–
Shareholder yield−31.4%0.00% (better)
Ownership
Held by institutions41.4%89.5%
Held by insiders–1.9%
Insider net buying, 12 months$4.0M (better)−$18.3M
Short interest, % of float–7.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.